HEART FAILURE IN SYSTEMIC LUPUS ERYTHEMATOSUS: RISK FACTORS AND DIAGNOSTIC FEATURES
https://doi.org/10.14412/1995-4484-2018-380-385
Abstract
With increased survival in patients with systemic lupus erythematosus (SLE), cardiovascular diseases have become the main causes of death. Heart failure (HF) is the final stage of the cardiovascular continuum; decompensation of this condition commonly results in death. Studies of HF, its frequency, risk factors, and diagnostic features in patients with SLE are extremely few. The paper details data on the definition, frequency, current classification, and the algorithm for the diagnosis of HF and comparatively analyzes the risk factors of the latter in the general population and among patients with SLE. HF diagnostic problems in this patient category and possible ways of their resolution are discussed.
About the Authors
T. A. Panafidina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
T. V. Popkova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Мареев ВЮ, Фомин ИВ, Агеев ФТ и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Сердечная недостаточность. 2017;18(1):3-40 [Mareev VYu, Fomin IV, Ageev FT, et al. Clinical guidelines. Chronic heart failure (CHF). Serdechnaya Nedostatochnost' = Russian Heart Failure Journal. 2017;18(1):3-40 (In Russ.)]. doi: 10.18087/rhfj.2017.1.2346
2. Ponikowski P, Voors AA, Anker SD, et al. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Российский кардиологический журнал. 2017;(1):7-81 [Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Rossiyskiy Kardiologicheskiy Zhurnal = Russian Journal of Cardiology. 2017;(1):7-81 (In Russ.)]. doi: 10.15829/1560-4071-2017-1-7-81
3. Фомин ИВ. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7-13 [Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Rossiyskiy Kardiologicheskiy Zhurnal = Russian Journal of Cardiology. 2016;(8):7-13 (In Russ.)]. doi: 10.15829/1560-4071-2016-8-7-13
4. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992 Nov;93(5):513-9. PMID:1442853. doi: 10.1016/0002-9343(92)90578-Y
5. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore). 1992 Sep;71(5):291-302. PMID:1522805. doi: 10.1097/00005792-199209000-00004
6. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997 Mar 1;145(5):408-15. PMID: 9048514. doi: 10.1093/oxfordjournals.aje.a009122
7. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronaryartery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 Dec 18;349(25):2407-15. doi: 10.1056/NEJMoa035611
8. Urowitz MB, Gladman D, Ibanez D, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus. 2007;16(9):731-5. doi: 10.1177/0961203307081113
9. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013 Aug;43(1):77-95. doi: 10.1016/j.semarthrit.2012.12.002. Epub 2013 Feb 17.
10. Bartels CM, Buhr KA, Goldberg JW, et al. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 2014 Apr;41(4):680-7. doi: 10.3899/jrheum.130874. Epub 2014 Feb 15.
11. Fernandez-Nebro A, Rua-Figueroa I, Lopez-Longo FJ, et al; EAS-SER (Systemic Diseases Study Group of Spanish Society of Rheumatology). Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry. Medicine (Baltimore). 2015 Jul;94(29):e1183. doi: 10.1097/MD.0000000000001183
12. Kim CH, Al-Kindi SG, Jandali B, et al. Incidence and risk of heart failure in systemic lupus erythematosus. Heart. 2017 Feb;103(3):227-33. doi: 10.1136/heartjnl-2016-309561. Epub 2016 Sep 9.
13. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999 Feb;42(2):338-46. doi: 10.1002/1529- 0131(199902)42:23.0.CO;2-U
14. Urowitz MB, Gladman D, Ibanez D, et al; Systemic Lupus International Collaborating Clinics. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Jun;62(6):881-7. doi: 10.1002/acr.20122
15. Dhakal BP, Kim CH, Al-Kindi SG, Oliveira GH. Heart failure in systemic lupus erythematosus. Trends Cardiovasc Med. 2017 Sep 6. pii: S1050-1738(17)30144-5. doi: 10.1016/j.tcm.2017.08.015 [Epub ahead of print].
16. Сальников АС, Рукавишников МЮ, Сорокина НН, Офицеров ВИ. Пептид NT-proBNP – маркер сердечно-сосудистой патологии. Новый набор реагентов «NTproBNP – ИФА – Бест». Новости «Вектор-Бест». Информационный бюллетень. 2011;1(59) [Sal'nikov AS, Rukavishnikov MYu, Sorokina NN, Ofitserov VI. The peptide NT-proBNP is a marker of cardiovascular pathology. A new set of reagents «NTproBNP – IFA-Best». Novosti «VektorBest». Informatsionnyy byulleten'. 2011;1(59) (In Russ.)].
17. Sagnella GA. Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann Clin Biochem. 2001 Mar;38(Pt 2):83-93. doi: 10.1258/0004563011900317
18. D’Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther. 2004 Feb;101(2):113-29. doi: 10.1016/j.pharmthera.2003.11.001
19. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988 Mar 3;332(6159):78-81. doi: 10.1038/332078a0
20. Potter LR, Abbey-Hosch S, Dickey DM, et al. Natriuretic peptides, their receptors, and cyclic guanosine monophosphatedependent signaling functions. Endocr Rev. 2006 Feb;27(1):47-72. Epub 2005 Nov 16. doi: 10.1210/er.2005-0014
21. Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003 Jun;17(9):1105-7. Epub 2003 Apr 22. doi: 10.1096/fj.02- 0796fje
22. Casco VH, Veinot JP, Kuroski de Bold ML, et al. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem. 2002;50(6):799-809. doi: 10.1177/002215540205000606
23. Goldenberg D, Miller E, Perna M, et al. Association of N-terminal pro-brain natriuretic peptide with cardiac disease, but not with vascular disease, in systemic lupus erythematosus. Arthritis Rheum. 2012 Jan;64(1):316-7. doi: 10.1002/art.33374
24. Chung CP, Solus JF, Oeser A, et al. N-Terminal Pro-Brain Natriuretic Peptide in Systemic Lupus Erythematosus: Relationship with Inflammation, Augmentation Index and Coronary Calcification. J Rheumatol. 2008 Jul; 35(7):1314-9. Epub 2008 Jun 1. PMCID: PMC2754266
25. Karadag O, Calguneri M, Yavuz B, et al. B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance? Clin Rheumatol. 2007;26(10):1701-4. Epub 2007 Feb 21. doi: 10.1007/s10067-007-0575-4
26. Панафидина ТА, Сохова МА, Попкова ТВ и др. Клиническое значение N-концевого фрагмента натрийуретического пептида у пациентов с системной красной волчанкой, не получающих патогенетическую терапию. Научно-практическая ревматология. 2017;55(4):376-81 [Panafidina TA, Sokhova MA, Popkova TV, et al. Сlinical significance of N-terminal fragment of natriuretic peptide in patients with systemic lupus erythematosus who do not receive pathogenetic therapy. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):376-81 (In Russ.)]. doi: 10.14412/1995-4484-2017-376-381
27. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009 Jul;13(32):1-207, iii. doi: 10.3310/hta13320
28. Butler J, Fonarow GC, Zile MR, et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014 Apr;2(2):97-112. doi: 10.1016/j.jchf.2013.10.006
29. Mohammed AG, Alghamdi AA, Aljahlan MA, Al-Homood IA. Echocardiographic findings in asymptomatic systemic lupus erythematosus patients. Clin Rheumatol. 2017 Mar;36(3):563-8. doi: 10.1007/s10067-016-3486-4. Epub 2016 Nov 19.
30. Ong ML, Veerapen K, Chambers JB, et al. Cardiac abnormalities in systemic lupus erythematosus: prevalence and relationship to disease activity. Int J Cardiol. 1992 Jan;34(1):69-74. doi: 10.1016/0167-5273(92)90084-G
31. De Godoy MF, de Oliveira CM, Fabri VA, et al. Long-term cardiac changes in patients with systemic lupus erythematosus. BMC Res Notes. 2013 May 1;6:171. doi: 10.1186/1756-0500-6-171
32. Puntmann VO, D’Cruz D, Smith Z, et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging. 2013 Mar 1;6(2):295-301. doi: 10.1161/CIRCIMAGING.112.000151. Epub 2013 Feb 12.
Review
For citations:
Panafidina T.A., Popkova T.V. HEART FAILURE IN SYSTEMIC LUPUS ERYTHEMATOSUS: RISK FACTORS AND DIAGNOSTIC FEATURES. Rheumatology Science and Practice. 2018;56(3):380-385. (In Russ.) https://doi.org/10.14412/1995-4484-2018-380-385
Views:
1122
Email this article 